Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Universal CD123 CAR-γδT cells
- Development stage
- Phase 1
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Universal CD123 CAR-γδT cells are an investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy being developed by Hebei Senlang Biotechnology. This therapy utilizes gamma-delta (γδ) T cells, a unique subset of T lymphocytes that possess innate-like properties and recognize antigens in an MHC-independent manner, thereby significantly reducing the risk of graft-versus-host disease (GvHD) compared to conventional alpha-beta (αβ) T cells. The cells are genetically engineered to express a CAR specific for CD123 (the alpha chain of the interleukin-3 receptor), a cell surface antigen highly expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells. By targeting CD123, these "off-the-shelf" cells aim to provide a potent and readily available treatment option for patients with refractory or relapsed AML, particularly those who have failed prior hematopoietic stem cell transplantation.
- Other names
- Universal CD123-targeted CAR-gamma delta T cellsAllogeneic CD123 CAR-γδT cellsUniversal CAR-γδT Cell Injection
02
Targets
IL3RA (Interleukin 3 Receptor)
Beyond the preview
Go deeper on Universal CD123 CAR-γδT cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Universal CD123 CAR-γδT cells.